Lercanidipine Hcl Viatris

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Hcl Viatris, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and is indicated for the management of hypertension in adult patients. It is typically prescribed when monotherapy or combination therapy is required to achieve target blood pressure.

GNH USA supplies Lercanidipine Hcl Viatris as a licensed, GDP‑compliant international pharmaceutical supplier. We provide the product to hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements to ensure consistent potency and safety for patients.

Lercanidipine Hydrochloride is used to treat conditions related to elevated arterial pressure. - Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: lowers high systolic pressure while maintaining diastolic stability. - Hypertension in patients with metabolic syndrome: assists in achieving blood pressure control alongside lifestyle measures.

Adverse reactions may occur with Lercanidipine use.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, or throat. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, itching, or anaphylaxis. - Cardiac conduction disturbances: heart block or arrhythmias.

Before initiating therapy, consider the following precautions. - Monitor blood pressure: check regularly after starting and after dose changes. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. - Caution in hepatic impairment: dose adjustment may be required. - Use with caution in elderly: increased sensitivity to hypotensive effects. - Review concomitant medications: assess for potential drug interactions. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Lercanidipine may interact with several medicines; assess the risk before co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Co‑administration with other antihypertensives: can cause excessive hypotension. - Grapefruit juice: may elevate drug exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring BP monitoring. - Beta‑blockers: combined use may need dose adjustments. - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic efficacy.